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Studies show that fibroblast growth factors (FGFs) control variety of cellular activities 
such as mitosis, cell differentiation, survival and angiogenesis. The FGF family consists 
of 23 different heparin-binding proteins. One of the most intensively studied members is 
human FGF-1 (hFGF-1) because of its critical role in the formation of blood vessels and 
cell proliferation in some types of cancer. The biological activities of FGFs are primarily 
mediated via interactions with fibroblast growth factor receptors (FGFR) and are a potent 
target in cancer. In this study, we report an efficient affinity column purification of 
hFGF-1 and the D2 domain of FGFR-2 from bacterial expression followed by SDS-
PAGE analysis. Steady state fluorescence results showed that both proteins were in their 




N HSQC NMR analysis of hFGF-1 was further
performed. The data confirmed the purity and well-conserved native state of the protein. 
The findings of this study can be used in designing hFGF-1 antagonists with competitive 
inhibition characteristics. These antagonists could result in possible inhibition of hFGF-1 







In recent times, cancer has become a worldwide concern affecting almost all 
countries. According to worldwide statistics collected by the World Health Organization 
(WHO) in 2012, there were about 14.1 million new people diagnosed with cancer, and 
approximately 8.2 million deaths caused by cancer (Fig. 1).
1
 Cancer is a class of complex 
genetic diseases characterized by uncontrollable cell growth.
1,2
 It damages cells and 
causes them to divide on their own accord which can result into the formation of tumors. 
Hundreds of different types of cancer have been identified and they are classified by the 























                           
 
 

















Targeting Cancer with Protein Biopharmaceuticals 
The birth of biotechnology since the 18
th
 century have recorded massive 
improvements in its applications.
3
 In the 1960s, there was an immediate increase in 
research involving the use of biotechnology in pharmaceutical industries. This increase 
led to a number of important findings, which gave researchers a  better understanding of 
the molecular activities of biological systems.
4
 Scientists also discovered that the human 
body has proteins that can fight against pathogenic microbes. This discovery gave rise to 
the development of biopharmaceuticals. Furthermore, it led to the increase of new 
techniques with the involvement of industrial applications in pharmaceutical areas. 
In the 1980s, the word “biopharmaceutical” was first used to describe a class of 
therapeutic drugs produced by biotechnological techniques such as genetic engineering.
5
 
Biopharmaceuticals are defined as medicinal products partially or fully manufactured 
from biological sources. These sources mainly include proteins and nucleic acids.
6
 
The onset of producing biopharmaceuticals started from making biosynthetic 
human insulin using recombinant DNA technology. Its trade name was Humulin and was 
officially deemed suitable for therapeutic use in 1982.
7
 Several biopharmaceuticals have 
since been produced to treat various types of diseases such hemophilia, 
thromboembolism, leukemia and more.
8
 
The number of biopharmaceuticals that has being produced for the global 
healthcare market has steadily increased since their advent in the 1980s. Among 
biopharmaceuticals, protein biopharmaceuticals are the fastest-growing category of drugs 
produced, targeting about 200 human diseases. Diseases such as Alzheimer's disease, 






 In 2013, $199.7 billion was invested globally towards 
biopharmaceutical research and development. It is projected that by the year 2020, a total 
of $497.9 billion will be invested globally towards biopharmaceuticals research. 
There have been massive breakthroughs in the diagnoses and treatment of cancer 
in the last few decades. Despite these advances there are still challenges to overcome. 
Studies show that tumors have developed resistance against current anticancer therapies. 
This increasing resistance necessitates the development of novel therapeutic anticancer 
agents. Recent studies have documented the overexpression of proteins such fibroblast 
growth factors (FGFs) in certain cancer such as breast cancer.
10
 The FGFs play important 
roles in the metasis and advancement of cancer cells via cell multiplication induced by 
FGF and FGF-angiogenesis. 
The Super Family of Fibroblast Growth Factors 
 
Armelin discovered fibroblast growth factors in pituitary extracts in 1973. 
Research  has continued to progress on this class of heparin-binding proteins.
11
 Due to 
continued research, 23 distinct FGFs have been discovered, namely FGF-1 to FGF-23. 
FGF-1 and FGF-2 are the most studied members of the super family. The molecular size 
of  FGFs is between 17 to 34 kDa and they have a common internal core of 140 amino 
acids, with 28 of the residues being highly conserved as well as 6 identical amino acids.
12
 
They are also all β-sheets without disulfide bonds (Fig. 2).
13
 
FGFs are involved in various essential cellular roles. They are important 
regulators in fetal development. They stimulate the formation of mesoderm and are 
involved in the regulation of cell migration to form the three germ layers. Studies have 






 Other crucial functions such as formation of the midbrain, 
lungs and limbs have been associated with FGFs. Their significant involvement in 
alveolar formation, branching of trachea and limb development has also been reported.
15–
18
 Recently, it has being suggested that FGF signaling is important during the early stages 
of neural induction in the development of the central nervous system. However, during 
the development of the midbrain, cell proliferation induced by FGFs is important in the 
formation of the midbrain-hindbrain boundary (MHB). Furthermore, FGFs have 
biological functions which include involvement in the process of wound healing, 
angiogenesis and also stimulation of cell survival factors: cell migration and 
differentiation.
19,20
 They have also been involved in pathological conditions, mainly 
diabetic retinopathy, rheumatoid arthritis and tumor growth. 
21
 Studies have demonstrated 
that the activities of FGFs are activated by two types of receptors on cell surfaces; the 
high affinity family of tyrosine kinase FGF receptors known as FGFRs and the low 









High Affinity Binding Fibroblast Growth Factor Receptors 
The Fibroblast Growth Factor Receptors (FGFR) family consists of five members, 
four of which are transmembrane with tyrosine kinase activity, (FGFRs 1-4) and the fifth 
with no tyrosine kinase activity. The FGFRs are about 70% identical in structure and 
typically consist of a well conserved extracellular region, an acid box, a transmembrane 
domain and an intracellular tyrosine kinase domain. Extracellularly they comprise of 
three immunoglobulin-like (Ig-like) domains numbered D1, D2, and D3 with a region in-
between the D1 and D2 of unique acidity known as acid box (Fig. 3). The tyrosine kinase 
domain contains both ATP binding and catalytic sites.
14, 22
 The differences in the 
structure and functions of FGFRs are caused by the alternative splicing of FGFR 
encoding mRNA and alternate promoter activity which gives rise to receptor isoforms.
23
 
The major FGF binding site on FGFRs is the D2 domain, D3 is known for determining 
the specificity of FGFs binding. The function of the D1 domain is not clear, although 
some studies suggest that it might inhibit FGF binding.
24
 Studies have shown that the 








Figure 3: Schematic structure of FGFR showing extracellular domain which contains of 
a signal peptide, three IG like domains (D1, D2, and D3), a transmembrane region and an 
internal tyrosine kinase domain 
 
Low Affinity Proteoglycan Family Receptors 
Researchers have shown that with the help of proteoglycans such as heparin or 
heparan sulfate, which function as low affinity cell surface receptors, FGFs are able bind 
to FGFRs.
15,26
 Heparin and heparin sulfates (HS) are glycosaminoglycans. Heparin 
consists of complex acidic polysaccharides characterized by a disaccharide repeating unit 
of α-d-glucosamine (Fig. 4). They are highly sulfated and negatively charged biological 
molecules.
27
 HS consists of a protein core attached to several carbohydrate moieties. 
They are also highly sulfated which makes them negatively charged. Heparins are usually 






 It is well documented that heparin and HS bind to a region of the D2 
domain of FGFRs named K18K loop because it is made up of positive amino acids.
24
 
Researchers have shown that there are physiological functions attached to heparin 
binding to FGFs. The two most important functions are protecting FGFs from degrading 
and creating specific reservoir of the proteins. Some researchers have shown that heparin 
interactions with FGFs protect them from heat since these growth factors are very 
unstable even at physiological temperature. The specific reservoir of FGFs is for 
regulation of FGF signaling which concentrates them so they are available in a large 
amount.
29 





















Signaling Mechanism of FGFs 
The binding of heparin or HS with FGF and FGFR to form a ternary complex is 
an important step in FGF signaling.
29
 The stabilization of FGFs is also enhanced by 
heparin which is crucial for FGF signal transduction.
26
 Once the ternary complex is 
formed, FGFR dimerization takes place followed by auto phosphorylation of the tyrosine 
residue on the FGFR.  
A series of downstream signaling takes place consisting of phosphoinositide 3-
kinase, Ras/mitogen-activated protein kinase (MAPK) among others. The signal 
transduction mechanism is shown in Figure 5. It has been proven that in the absence of 
cell surface proteoglycan heparan sulphate, a significant reduction in FGFR activity 
involving cell proliferation, mitogenesis and wound healing is noticed.
30,31
 










































Figure 5: Signaling Mechanism of FGFs. Formation of ternary complex of FGF: FGFR: 
HSPG leading to the activation of intracellular kinase domains and auto phosphorylation 
of the tyrosine amino acid residues. Downstream events lead to DNA replication and then 








Human Fibroblast Growth Factor-1 (hFGF-1) 
 
Human fibroblast growth factor (hFGF-1) is also known as acidic fibroblast 
growth factor because it contains many acidic amino acids like lysine.  The hFGF-1 is the 
most studied member of the FGF family. The hFGF-1 is a non-glycosylated polypeptide 
consisting of 154 amino acids residues made up 12 β strands.  It is a powerful mitogen 
and is involved in the stimulation of DNA synthesis and cell proliferation in cell lines 
such as fibroblasts, myoblasts, chondrocytes.
32
 It is considered a pro-angiogenic drug 
candidate in the treatment of wound healing and peripheral artery diseases.
33,34
  
Various studies have shown that there is overexpression of hFGF-1 in tumors 
such as breast cancer. Their interactions with FGF receptors as described in previous 
paragraphs are crucial in the cell proliferation and differentiation which in turn promotes 





Objective of Study 
Overexpression of FGFs and its receptors (FGFRs) has been associated with the 
promotion of several types of tumor cells. hFGF-1 especially has been associated as a 
pivotal component in the development of lung and breast cancer among others. 
Researchers have come up with different methods such as small molecule drugs 
inhibiting the interactions of these proteins with their receptors (FGFRs) which will in 
turn inhibit FGF induced cell proliferation in tumorous regions.  
New studies show that hFGF-1/FGFRs interactions can be considered an 




interactions in cancer progression. In order to design such antagonists, purified forms of 
hFGF-1 and D2 domain (hFGF-1 binding site) is important. The objective of this study is 
to show a method for large scale recombinant protein purification using heparin and 
Nickel  Nitrolotriacetic acid (Ni-NTA) affinity column chromatography. This method of 
chromatography is to achieve purification of human fibroblast growth factor-1 and the D2 
domain of fibroblast growth factor receptor-2 in biologically active conformations. The 
hFGF-1 was also expressed isotopically in the form of 
15




















This chapter consists of the materials and methods used during this study. Table 1 is the 
list of all the chemicals used in this study and company they were purchased from. 
  Materials 
  The microorganism used in this study was recombinant Escherichia coli [BL21 (DE3)]     
  This was brought from Invitrogen. 
  
Chemicals Company 
Ammonium chloride EMD Chemicals 
Ammonium sulfate EMD Chemicals 
Ampicillin Amersco 
Brom phenol blue Allied Chemicals 
2-mercatoethanol J.T Baker 
Calcium chloride EMD Chemicals 
Chloramphenicol Sigma Aldrich 
Dextrose EMD Chemicals 
Disodium hydrogen phosphate EMD Chemicals 
Glycerol EMD Chemicals 
Glycine EMD Chemicals 
Heparin sepharose resin GE Healthcare 
Isopropyl β-D-1Thiogalactopyranoside (IPTG) Amersco 
Luria Broth (LB) Novagen 
Monobasic and dibasic sodium phosphate EMD Chemicals 




Methanol EMD Chemicals 
Ni-NTA resin GE Healthcare 
Potassium sulfate EMD Chemicals 
Potassium di-hydrogen phosphate EMD Chemicals 
Potassium hydrogen phosphate EMD Chemicals 
Brilliant Blue R 250 Dye  Fisher Biotech 
Riboflavin EMD Chemicals 
Sodium azide EMD Chemicals 
Sodium chloride J.T. Baker 
Sodium dodecyl sulfate (SDS) EMD Chemicals 
Temed EMD Chemicals 
Thiamine Acros Organic 
Tris Base Cal Biochem 
Trichloroacetic acid EMD Chemicals 
Urea J.T Baker 
 
Table 1: The list of chemicals used in this study and the respective companies they was 
obtained from 
 
The methods and instrumentations used in this study are further discussed in this section 
of the chapter.  
Methods 




All pH adjustment was achieved using a pH meter 
0.5 M Monobasic Buffer (NaH2PO4.2H2O) (FW: 156 g): A sample of 30.00 g 
monobasic sodium phosphate was weighed and dissolved in nanopure water of about 400 
ml in a conical flask. The total volume was made up to 500 ml and poured into a clean 
labelled glass bottle and stored at 23 
o
C. 
0.5 M Dibasic Buffer (Na2HPO4.12H2O) (FW: 358 g): A sample of 35.50 g of dibasic 
sodium phosphate was weighed into a conical flask and dissolved in nanopure water of 
about 400 ml. The total volume was made up to 500 ml and transferred into a clean 
labelled glass bottle and stored at 23 
o
C. 
0.5 M Phosphate Buffer (500 ml): A mixture of 50 ml of 0.5 M monobasic and 450 ml 
of 0.5 M dibasic was made (1:9 ratio of monobasic and dibasic). The pH was adjusted to 
7.2 and the solution was poured into a labelled clean glass bottle and stored at 23
 o
C. 
10 mM Phosphate Buffer (1 L): A solution of 20 ml 0.5 M phosphate buffer was 
measured into a conical flask using a 1 L graduated cylinder. Nanopure water was added 
to make up volume to 1 L. This mixture was stirred well and transferred into a clean 
labelled glass bottle and pH was adjusted to 7.2. 
5 M Sodium Chloride (500 ml): A sample of 146.0 g sodium chloride crystals was 
weighed into a conical flask and dissolved with about 400 ml of nanopure water. The 
solution was made up to 500 ml and poured into a clean labelled glass bottle. 
0.8 M NaCl in 10 mM Phosphate Buffer (500 ml): A solution of 80 ml 5 M sodium 
chloride was mixed with about 350 ml of 10 mM phosphate buffer in a conical flask. The 
volume was made up to 500 ml with 10 mM phosphate buffer and pH was adjusted to 




1.5 M NaCl in 10 mM Phosphate Buffer (500 ml): A solution of 150 ml 5 M sodium 
chloride was mixed with about 250 ml of 10 mM phosphate buffer in a conical flask. The 
volume was made up to 500 ml with 10 mM phosphate buffer and pH was adjusted to 
7.2.  The solution was poured into a clean labelled glass bottle. 
1 M Sodium Azide (100 ml): A sample of 6.500 g of sodium azide was weighed into a 
250 ml conical flask and dissolved with about 70 ml of nanopure water. Using a 
graduated cylinder, the volume was made up to 100 ml. The solution was poured into a 
clean labelled glass bottle. 
Dialysis Buffer (4 L): A solution of 80 ml 5 M sodium chloride (100 mM), 80 ml of 0.5 
M phosphate buffer (10 mM), 26.4 g of ammonium sulfate (50 mM) and 4 ml of 1 M 
sodium azide were measured into a 4 L conical flask. About 3.5 L of nanopure water was 
added and the solution was mixed well and total volume was made up to 4 L with 
nanopure water and then pH was adjusted to 7.2. 
 
 
Construction of hFGF-1 and D2 domain of FGFR-2  
Human FGF-1 (GenBank #X59065) of residues 14-154 from full length hFGF-1 
and D2 domain of human FGFR-2 (GenBank #AK026508) of residues 145-259 from full 
length FGFR-2 cDNAs were made following standard procedures. They were cloned into 
pJExpress414 vectors (DNA2.0) and transformed into BL21(DE3) E. coli cells for 
overexpression.
35
 The gene sequences were optimized using DNA2.0 codon bias 
algorithm to maximize the yield of the proteins prior to cloning.
36
  




Tris (Tris hydroxyl methyl) Amino Methane (pH 8.8): A sample of 24.22 g tris base 
was weighed into a conical flask and dissolved in about 150 ml of nanopure water and 
mixed well. The solution was made up to 200 ml with nanopure water and pH was 
adjusted to 8.8. Solution was transferred to a clean labelled glass bottle and stored at 4 ºC 
in a refrigerator. 
Tris (Tris hydroxyl methyl) Amino Methane (pH 6.8): A sample of 24.22 g tris base 
was weighed into a conical flask and dissolved with about 150 ml of nanopure water and 
mixed well. The solution was made up to 200 ml with nanopure water and pH was 
adjusted to 6.8. Solution was transferred to a clean labeled glass bottle and stored at 4 ºC 
in a refrigerator. 
10% Sodium Dodecyl Sulfate: A sample of 4 g of sodium dodecyl sulfate was weighed 
into a 50 ml falcon tube and dissolved with 35 ml of nanopure water. The mixture was 
vortexed well and the volume made up to 50 ml of nanopure water and stored at room 
temperature.  
10% Ammonium per sulfate (APS): A sample of 1.000g ammonium per sulfate was 
weighed into a 50 ml falcon tube and dissolved with 10 ml of nanopure water; solution 
was transferred into a glass bottle and stored at 4ºC in a refrigerator. 
Staining Buffer: A sample of 2.500 g R250 dye, 450 ml methanol and 100 ml glacial 
acetic acid were weighed and measured respectively into a 1 L conical flask and mixed 
well. About 500 ml of nanopure water was added and mixed well; total volume was made 




Distaining Buffer: A solution of 150 ml methanol, 75 ml glacial acetic acid and 775 ml 
of nanopure water were measured and mixed well in a 1 L conical flask. Solution was 
stored at room temperature. 
10X Running Buffer Stock: A sample of 30.80 g tris base, 166.0 g glycine, 10.00 g SDS 
were weighed into a conical flask and dissolved with about 500 ml of nanopure water and 
the solution was mixed well using a magnetic stirrer. The final volume was made up to 
1000 ml with nanopure water and mixed well. The solution was stored at room 
temperature. 
Running Buffer for SDS-PAGE: A solution of 930 ml nanopure water was measured 
using a graduated cylinder into a conical flask and 70 ml of 10X running buffer stock was 
added and mixed thoroughly.  
0.1% Bromo phenol Blue: A sample of 50.00 mg of bromo phenol blue was weighed 
and dissolved with 50 ml of nanopure water. The solution was mixed thoroughly and 
transferred into a clean glass bottle and stored at room temperature.  
Loading Dye Stock: A solution of 0.6 ml of tris base (pH 6.8), 1 ml glycerol and 2 ml 
10% SDS were measured and mixed well with 5.4 ml nanopure water. Solution was 
stored at room temperature.  
2X Loading Dye (500 μl): A solution of 475 μl of loading dye stock was mixed well 
with 25 μl 2-mercaptoethanol. 
150% Trichloroacetic acid: A sample of 15.00 g of trichloroacetic acid was weighed 





8 M Urea: A sample of 9.600 g of urea was weighed into a conical flask and dissolved 
with about 15 ml of nanopure water and mixed well. Total volume was made up to 20 ml 
with nanopure water and stored at room temperature. 
Media Preparation 
Luria broth Media (1 L): A sample of 25.00 g of LB broth was weighed out in a 2000 
ml conical flask and about 500 ml of nanopure water was added. The solution was mixed 
well and using a measuring cylinder it was made up to 1 L and autoclaved.  
Minimal Media (500 ml): A sample of 13.00 g of Potassium Dihydrogen Phosphate 
(KH2PO4), 10.00 g of Potassium Hydrogen Phosphate (K2HPO4), 9.00 g of Sodium 
Hydrogen Phosphate (Na2HPO4), 2.400 g of Potassium Sulfate (K2SO4) and 0.5000 g of 
15
N Ammonium Chloride (NH4Cl) were accurately weighed out into a 2000 ml conical 
flask and dissolved with about 400 ml of nanopure water and mixed well. The solution is 
made to mark of 500 ml with nanopure water, mixed well and autoclaved. When the 
media was cooled to room temperature, 400.0 mg of dextrose, 10 μl of 1 M calcium 
chloride (CaCl2), 1 ml of 1 M magnesium chloride (MgCl2), 500 μl of  5.000 mg/ml 
thiamine, 68 μl of riboflavin, 100 μl of 50.00 mg/ml ampicillin and 100 μl of 34.00 
mg/ml chloramphenicol were added. 
Expression and solubility of hFGF-1 
E. coli cells were transformed with pJExpress414 vector containing the hFGF-1. 
The proteins were first grown in 100 ml LB medium containing 1µl/ml of 
chloramphenicol and ampicillin. Induction of the proteins was achieved by addition of 
0.5 mM/L of Isopropyl-β-D-thiogalactopyranoside (IPTG) once the absorbance of the 




for 12 more hours until absorbance at 600 nm was about 1.4. The cells were harvested 
and lysed by sonication (Fig. 6). The SDS-PAGE analysis of expression and solubility of 
hFGF-1 was done. 
Purification of recombinant hFGF-1 using heparin affinity column chromatography  
Human FGF-1 was expressed in soluble form and the purification was achieved 
by heparin sepharose affinity column. The clear soluble fraction of bacterial cell lysate 
was loaded onto a heparin sepharose affinity column and incubated at room temperature 
for an hour. The hFGF-1 was bound to heparin sepharose in the column and washed with 
elution buffers (pH 7.2) of increasing ionic strength; 10 mM phosphate buffer next was 
10 mM phosphate buffer containing 0.8 M NaCl, finally with 10 mM phosphate buffer 
containing 1.5 M NaCl. The protein was eluted with the buffer containing 1.5 M NaCl 
(Fig. 7). The temperature was maintained at about 4 
o
C throughout the process of 
purification. SDS-PAGE analysis of all samples from the elution fraction was done. 
Results from the SDS-PAGE analysis that showed the fraction/fractions with the 
highest concentrations and single bands were subjected to desalting by dialysis in 
phosphate buffer containing 100 mM NaCl (pH 7.2). The conformation and concentration 
of the final protein sample was assessed using PerkinElmer spectro-fluorometer and UV-
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E. coli cells were transformed with pJExpress414 vector containing D2. The 
proteins were first grown in 100 ml LB medium containing 1µl/ml of chloramphenicol 
and ampicillin. Induction of the proteins was achieved by addition of 0.5 mM/L of 
Isopropyl-β-D-thiogalactopyranoside (IPTG) once the absorbance of the growing culture 
reached about 0.5 at 600 nm. The culture was further incubated at 37 °C for 12 more 
hours until absorbance at 600 nm was about 1.4 (Fig. 8). The cells were harvested and 
lysed by sonication. SDS-PAGE analysis of the expression and solubility of D2 domain 
was done.  
 
Purification of D2 domain of FGFR-2 using Ni-NTA and heparin affinity column 
chromatography 
 
The protein lysate from sonication was centrifuged and the supernatant was 
discarded because D2 was expressed in inclusion bodies (the insoluble part of bacterial 
cell lysate) and so they were in the pellet. Purification was achieved by denaturation of 
the inclusion bodies using 20 ml of 8 M urea. The suspension was then centrifuged and 
the supernatant loaded onto a nickel affinity column and incubated at room temperature 
for one hour. The refolding of the protein was achieved by a stepwise reduction of urea 
concentration (8 M to 0 M) and incremental increase of imidazole (20 mM to 500 mM) 
since D2 was His-tagged. The protein was eluted by the buffer with 500 mM imidazole in 
it. Further purification was facilitated by incubating the 500 mM imidazole fraction onto 
a heparin sepharose column and washed with 10 mM phosphate buffer (pH 7.2) to 
remove contaminating proteins (Fig. 9). D2 was bound to heparin sepharose in the 
column and was eluted with 10 mM phosphate buffer containing 1.5 M NaCl.  Results 




by dialysis in phosphate buffer containing 100 mM NaCl (pH 7.2). The conformation and 
concentration of the final protein sample was assessed using PerkinElmer spectro-
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Figure 9: Schematic representation of D2 purification by Ni-NTA affinity 
chromatography 











that provides the fingerprint of protein molecules. The spectrum result of the active NMR 
protein displays 
1
H along one axis, while the other axis is devoted to either of the two 




N). HSQC-NMR is 
useful to detect the binding interface between protein-protein and protein-ligands such as 
drugs. This can be achieved by overlapping the HSQC spectrum of the free protein with 
the one bound to the ligand, then analyzing for changes in the chemical shifts of some 
peaks can be observed.  
15
N Labelled Human FGF-1 Expression and Purification 
 
The hFGF-1 were expressed and in order to make them NMR active, the proteins 
were grown in 
15





Minimal media was prepared as previously discussed. The recombinant E. coli used was 
ampicillin and chloramphenicol resistant. Ampicillin and chloramphenicol were added to 
the media to inhibit the growth of other bacteria. A preculture of 100 ml minimal media 
containing the bacterial cells was grown for about 14 hours. Purification of 
15
N labelled 
hFGF-1 was done following procedure as unlabeled hFGF-1 purification discussed 
previously. After dialysis, the sample was concentrated using Amicon ultra centrifugal 
filters. The membranes in the filters were soaked for 1 hour with nanopure water. Next, 
they were soaked in dialysis buffer for 30 minutes. The protein sample was transferred 
into the filters and parafilm was used to cover them. The tubes were then centrifuged at 
7,000 rpm for about 12 minutes. This procedure was continued until sample was 










Figure 10: Making N
15 




RESULTS AND DISCUSSION 
 
Biopharmaceutical drug research requires an approach for obtaining hFGF-1 and 
FGFR in pure forms for research purposes. Next, these purified proteins were studied 
Supplement bacterial medium 
with N
15




using several biophysical techniques to understand their structural-functional 
relationship. This is useful developing novel targets to cure diseases these proteins are 
associated with. 
Expression and Purification of hFGF-1  
The hFGF-1 construct used in this present study is 140 amino acids long, and is 
derived from the full length human FGF-1. The recombinant E. coli was amplicon and 
chloramphenicol resistant hence amplicon and chloramphenicol were added to the media 
to inhibit the growth of other bacteria. Addition of Isopropyl β-D-thiogalactopyranoside 
(IPTG) to the growing media containing hFGF-1 induced lac operon. This increased the 
production of hFGF-1 while suppressing other genes. SDS-PAGE analysis of hFGF-1 
expression showed that most of the protein was expressed in the soluble portion of the 
media after lysing and centrifugation (Fig. 11). Since hFGF-1 is a positively charged 
molecule and heparin is negatively charged, purification was facilitated by heparin 
affinity column chromatography. hFGF-1 bound to heparin tightly and the undesired 
proteins were removed by first running the wash buffer [10 mM phosphate buffer (pH 
7.2)]. With increasing sodium chloride gradient concentration of 0 to 1.5 M, all unwanted 
proteins were removed and hFGF-1 was finally eluted with buffer containing 1.5 M 
NaCl. SDS-PAGE analysis of purified hFGF-1 showed an intense single band 
corresponding to a molecular weight of ~16 kDa. (Fig. 12). This fraction was further 
desalted with 100 mM NaCl buffer. Using a PerkinElmer Spectro-fluorometer the 
conformation of the purified protein was shown to be in native conditions and well 
folded. The concentration of hFGF-1 was quantified using UV-Vis spectroscopy 




coefficient value of hFGF-1 which is 1.28, l is path length of the UV cuvette used
38
. The 
total yield of purified hFGF-1 was about 0.82 mg per ml and about 19 mg per one liter 
culture. The purified sample was finally allocated into eppendorf tubes and stored at -80 





















Figure 11: SDS-PAGE analysis of hFGF-1 expression. Lane M represents the molecular 
weight marker; lane 1, uninduced sample; lane 2, induced sample; lane 3, lysate of 
















Figure 12: SDS-PAGE analysis of hFGF-1 purification using heparin column. Lane M, 
represents the molecular weight marker; lane 1 represents the protein band contained in 
fraction collected as flow through; lane 2, represents the protein band contained in 
fraction eluted in 10 mM phosphate buffer; lane 3, represents the protein band contained 
in fraction eluted in buffer containing 0.8 M NaCl and 10 mM phosphate buffer; lanes 4-
7, represents the protein bands contained in fractions eluted in buffer 1.5 M NaCl and 10 















The Expression and Purification of D2 domain of FGFR-2 
The D2 domain construct used in this study was 114 amino acids long from the 
full length human FGFR-2. SDS-PAGE analysis of the bacterial cells induced by IPTG 
showed that most of the protein was expressed in the insoluble fraction of the protein 
lysate (inclusion bodies) after sonication and centrifugation (Fig. 13). 
The insoluble pellet was dissolved in 8 M urea which denatures and unfolds the 
protein. Proteins are denatured by urea by altering the arrangement of water molecules 
which makes them move into the hydrophobic core of the protein and weakening the 
intermolecular bonds of the peptide. This weakens the secondary and tertiary 
conformation of the protein. The denatured D2 was loaded onto a Ni-NTA (Nickel 
Nitrilotriacetic acid) affinity column, since D2 was His-tagged causing it to be negatively 
charged because of the imidazole rings on histidine. Refolding of the protein was 
facilitated by incubating the denatured protein fraction on an Ni-NTA affinity column 
and refolding using a linear gradient decrease of urea (8 M to 0 M) and increase of 
imidazole (20 mM to 500 mM). The concentration of urea was gradually decreased to 
refold the protein in the column while the concentration of imidazole was increased to 
elute the protein. The free imidazole in the buffer competes with D2 for nickel. The 
column was washed with 20 mM phosphate buffer (pH 7.2) which contained 20 mM, 50 
mM, 100 mM imidazole concentrations and finally the protein was eluted in 500 mM 
imidazole concentration. Increasing concentrations of imidazole were used for two main 
purposes; first, to reduce the concentration of urea to get the protein back into native 
conformation. Second, it was used to elute the protein by competing for the positively 




incubating the 500 mM imidazole fraction onto a heparin affinity column. The column 
was washed with phosphate buffer; the impurities were eluted by the 10 mM phosphate 
buffer (pH 7.2) and 10 mM phosphate buffer containing 0.8 mM sodium chloride (pH 
7.2). The D2 domain was eluted with 10 ml phosphate buffer containing 1.5 M sodium 
chloride (pH 7.2) and yielded an intense single band on SDS-PAGE corresponding to a 
molecular mass of ~ 13 kDa (Fig. 14). Using a PerkinElmer Spectro-fluorometer the 
conformation of the purified protein was shown to be in native conditions and well-
folded. The concentration of hFGF-1 was quantified using UV-Vis spectroscopy 
following Beer’s law equation: A= Ecl, where A is absorbance at 280 nm, E is extinction 




, l is path length of the UV cuvette used 
38
. The total yield of purified D2 was about 17 mg per 1 liter culture. The purified sample 












Figure 13: SDS-PAGE analysis of D2 domain of FGFR-2 expression. Lane M represents 
the molecular weight marker; lane 1 represents the uninduced sample; lane 2 represents 
the induced sample; lane 3 represents the lysate of induced sample soluble fraction; lane 















Figure 14: SDS-PAGE analysis of D2 domain purification using nickel affinity (lanes 1-
6) and heparin affinity (lanes 7-10) columns. Lane M represents the molecular weight 
marker; lane 1 represents the protein band contained in fraction collected as flow 
through; lanes 2-5 represent the protein bands contained in fractions eluted in 20 mM, 50 
mM, 100 mM, 500 mM imidazole concentration, respectively from the nickel column. 
Lane 7-10 represents the fractions collected from heparin column. Lane 7 represents 
protein bands contained in fraction collected as flow through; lane 8 represents the 
protein bands contained in fraction eluted in 10 mM phosphate buffer; lane 9 represents 
the protein band contained in fraction eluted by the 10 mM phosphate buffer with 0.8 M 
NaCl concentration; and lane 10 represents the protein bands contained in fraction eluted 




Expression and Purification of 
15 
N labelled hFGF-1  




E. coli cells were grown in 100 ml of minimal media preculture overnight. It was 
further grown for about 14 hours. The procedure described previously for the expression 
and purification of unlabeled hFGF-1 was followed for the rest of the experiment. 
Expressing and purification of the labelled protein was analyzed by SDS-PAGE (Figs. 15 
and 16). The yield was quantized by UV-Vis spectroscopy to be about 22 to 25 mg per 


















Figure 15: SDS-PAGE analysis of 
15
N labelled hFGF-1 expression. Lane 1 represents 
the uninduced sample; lane 2 represents the induced sample; lane 3 represents the lysate 

















Figure 16: SDS-PAGE analysis of 
15
N labelled hFGF-1 purification using heparin 
column. Lane M represents the molecular weight marker; lane 1 represents the protein 
band contained in fraction collected as flow through; lane 2 represents the protein band 
contained in fraction eluted in 10 mM phosphate buffer; lane 3 represents the protein 
band contained in fraction eluted by the buffer with 0.8 M NaCl and 10 mM phosphate 
buffer; lanes 4-7 represent the protein bands contained in fractions eluted in 10 mM 









Biophysical Characterization of Expressed hFGF-1 and D2 domain 
  1         2      3          4        5       6       7    





Biophysical characterization of proteins as regards structural studies is to 
determine the state and conformation of the protein purified. This gives information 
about the structural conformation of the protein if it is in folded, partially folded, or 
unfolded state, the purity and the stability of the protein is also provided. Fluorescence 
spectroscopy was used to assess the confirmation of the unlabeled hFGF-1, D2 domain 
and 
15
N labeled hFGF-1. These proteins contain two amino acids that fluoresce: 
tryptophan and tyrosine. These amino acid residues have different absorption and 
emission wavelengths in the folded and unfolded states which help in tracking the tertiary 
structural changes in the protein molecule. The emission spectrum of hFGF-1 at ~ 308 
nm in its native state is dominated by a tyrosine emission peak. In the completely 
unfolded state, hFGF-1 exhibits an emission spectrum dominated at ~ 350 nm which is 
because of fluorescence of a single well-conserved tryptophan at position 121 in the full 
form of the primary sequence (Fig. 17). 
The well-folded D2 domain has an emission spectrum at between 338 to 342 nm 
but in its completely unfolded state it exhibits an emission spectrum dominated at ~ 350 



















































 The same procedure was followed for expression and purification of unlabeled 
hFGF-1. Enriching vitamins were included in the media.  
 
HSQC-NMR sample preparation 
 A 700 MHz spectrometer was used. Concentration of the protein sample analyzed 
was 1.6 mg/ml and was prepared in 10 mM phosphate buffer containing 10 mM sodium 
chloride (pH 7.2). The NMR data were acquired at temperature of about 25 ± 0.5 ºC. The 
spectrum obtained showed that the purified hFGF-1 was in native state and properly 























N HSQC spectrum representing the finger-print of the backbone 















Human fibroblast growth factor-1, a prototype of FGF family is a powerful 
mitogen that is considered a potent angiogenic drug candiaite. There have being reports 
of overexpression of hFGF-1 in cancers such as breast cancer. The protein binds mainly 
to the D2 domain of FGFRs. These two heparin binding proteins were successfully 
expressed and purified. Human FGF-1 was expressed in the soluble fraction of the 
bacterial lysate and was purified using heparin sepharose affinity chromatography. N 15 
labelled hFGF-1 was also expressed and purified. The D2 domain of FGFR was 
expressed in the insoluble fraction of the bacterial lysate and was purified using nickel 
affinity chromatography. SDS-PAGE analysis of both proteins showed that were 
expressed in pure forms. Data from fluorsecence analysis showed that the proteins were 
properly folded and were in biologically active conformations. The total yield of hFGF-1 
was 32.7 mg per 1 litre culture. The yield of D2 domain was 18 mg per 1 litre culture. 
The findings of this study will facilitate research towards understanding the 
regulation of heparin binding proteins mediated biological activities. Since hFGF-
1/FGFRs interactions have been considered a target for cancer therapy, the efforts to 
develop antagonists targeting this interaction have been on an increase; hence, producing 









There has been an increase of research in the area of protein biopharmaceuticals 
development. Proteins such as fibroblast growth factors and their receptors, particularly 
human FGF-1, as stated previously are important target in cancer therapy.  The 
availability of purified forms of these proteins will enhance research about them. The 
hFGF-1’s structure and interactions with its receptors can be studied using various 
biophysical techniques such as proteolytic digestion, biacore. Data from these techniques 
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